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Abstract
For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed
chemotherapyregimensforpatientcare,withlimitedeffect.Five-yearsurvivalratesforthesepatientsare
notencouraging. However,for asubgroup ofthese patients, therehavebeen radical changesoverrecent
years. Our understanding of the basic pathology behind NSCLC at the molecular level has offered up a
host of new molecularly targeted therapies, which are revolutionizing this area of cancer care. Results
fromrecentclinicaltrials provide hopefor NSCLCpatientsharboringoncogenic translocations involving
the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. Just as inhibition of the breakpoint
cluster region–ABL complex has changed the face of chronic myeloid leukemia diagnosis, oncogenic ALK
fusions offer a step forward in the diagnosis and treatment of ALK-positive NSCLC. This article discusses
the current knowledge and potential implications concerning ALK inhibitors and NSCLC.
Lung cancer and a new era of treatment
Figures released by the American Cancer Society for 2008
reported 1.6 million new lung cancer cases worldwide.
Indeed, lung cancer is the leading cause of cancer death
in men and the second leading cause of cancer death in
women, with estimated deaths approaching 1.4 million
worldwide in 2008 [1]. Clinically, primary lung cancer is
divided into small-cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC), and patients receive
differential therapy based on these criteria. NSCLC is an
umbrella term for a number of tumor types that together
account for approximately 80% of lung cancers. These
include the three main subtypes of squamous-cell lung
carcinoma, large-cell lung carcinoma, and adenocarci-
noma [2]. Adenocarcinoma accounts for approximately
40% of all NSCLC and is more prevalent among people
who have never smoked [3]. For many years, treatment
for advanced or metastatic NSCLC has employed chemo-
therapy regimens for patient care with limited effect.
Five-year survival rates for these patients are not encour-
aging. However, for a subgroup of these patients, there
have been radical changes over recent years. Our under-
standing of the basic pathology behind NSCLC at the
molecular level has offered up a host of new molecularly
targeted therapies, which are revolutionizing this area
of cancer care. Activating EGFR (epidermal growth factor
receptor) mutations in NSCLC provided the first opport-
unity to generate molecularly defined treatments such as
the inhibitors gefitinib and erlotinib [4-7]. Results from
recent clinical trials provide hope for NSCLC patients
harboring oncogenic translocations involving the ana-
plastic lymphoma kinase (ALK) receptor tyrosine kinase.
Just as inhibition of the BCR–ABL (breakpoint cluster
region–c-abl oncogene 1, non-receptor tyrosine kinase)
complex has changed the face of chronic myeloid leuke-
mia diagnosis, oncogenic ALK fusions offer a step forward
in the diagnosis and treatment of ALK-positive NSCLC.
Recent advances in drug development, particularly those
targeting ALK, which will be discussed here, have led to
significantchangesinthewayweviewthispatientpopula-
tion and their future therapeutic prospects.
ALKwasfirstdescribedasanoncogeneinhumancancerin
the 1990s, with the description of the nucleophosmin–
ALK (NPM-ALK) fusion gene in anaplastic large-cell
lymphoma (ALCL), resulting in the acronym ALK [8,9].
Since then, a large number of ALK translocations in a
growing variety of tumor types have been described, in
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1which the uniting theme is the dimerization and inapp-
ropriate ligand-independent activation of ALK tyrosine
kinase activity by the fusion partner in question [10-13].
As well as a role in hematological malignancies, ALK
translocations are also found in a number of solid tumor
types, including NSCLC, squamous cell carcinoma, and
more recently thyroid cancer [14-18]. While initially
considered to be rather unusual, the identification of
fusions suchasTMPRSS2–ERG (transmembrane protease,
serine 2–ETS-related gene) in prostate cancer [19] suggest
thatwemayhaveunderestimatedtheiroccurrenceinsolid
tumors and may find more of these translocations in
coming years with the application of the latest sequencing
technologies.
ALK and NSCLC
The appearance of ALK fusion oncoproteins in NSCLC
was first described in 2007 in two independent studies
with quite different approaches [15,16]. While Soda et al.
[15] used classical tumor DNA library transformation
assays to identify echinoderm microtubule-associated
protein-like 4 (EML4)–ALK, Rikova et al. [16] carried out
one of the initial global phosphotyrosine proteomic
analyses of NSCLC cell lines, identifying a number of
oncogenic lesions including EML4–ALK and TRK-fused
gene–ALK (TFG-ALK).
Prior to the identification of ALK fusion proteins in
NSCLC, the patient population presenting with ALK
fusions, such as NPM–ALK in ALCL, was limited. This
number changed significantly with the consideration of
an estimated 3–13% of NSCLC patients [15,16,20-23].
Calculated at a rate of 5% of ALK translocations and
based on 2008 American Cancer Society figures [1],
NSCLC cases amenable to ALK-directed therapies would
be predicted to reach in the order of 80,000 new lung
cancer patients per year worldwide.
The NSCLC patient group presenting with ALK transloca-
tions is somewhat different from the more commonly
appreciated smoking-related lung cancer population. It is
now recognized that there is an increasing population of
‘non-smoking-associated lung cancer’ NSCLC patients
in which aberrations such as EML4–ALK and activating
EGFR mutations are enriched.This population isgenerally
predominantly female and tumors are often adenocarci-
nomas [21,24,25].
In an attempt to better appreciate the frequency of various
defined mutations in NSCLC of the adenocarcinoma type,
the National Cancer Institute’sL u n gC a n c e rM u t a t i o n
Consortium is examining 1,000 tumors for a number of
driver mutations, including ALK translocations. Their most
recent results, based on 830 patients, suggest that 60% of
tumors exhibit driver mutations including 25% KRAS
(v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog),
23% EGFR,a n d6 %ALK rearrangements [23]. This also
meansthat,in40–50%ofNSCLC,thereareasyetunknown
drivers,perhapsasaresultoflossoftumorsuppressorgenes
and epigenetic misregulation, serving as a stern reminder
that there are still many questions to be answered.
ALK translocations, fusion proteins, and
diagnostics in NSCLC
As mentioned above, many molecularly different ALK
translocations have been described in a number of tumor
types. While the complete picture is far from clear, the
datathusfarindicatethatdifferenttumortypeshavetheir
own particular patterns of ALK fusion partners. This is
certainly true for ALK fusions in NSCLC, where by far the
most common fusion partnership is EML4–ALK [15,16],
with others such as TFG [9] and kinesin family member
5B (KIF5B) [26,27] being less frequently observed. The
EML–ALK translocation fusions are particularly complex
with a number of different break points [28]. While one
mightenvisionthatotherALKtranslocationpartnersmay
be identified in future studies, a comprehensive study
argues against involvement of the common partners such
as NPM in NSCLC [29]. To date, a number of studies
suggestthattogethertheseALKtranslocationsaccountfor
3–13% of NSCLC [15,16,20-23,29-34].
One critical area of activity is the development of robust
and accurate diagnostics for the routine identification
of ALK translocations in lung adenocarcinoma. Cur-
rently, fluorescence in situ hybridization, immunohisto-
chemistry, and reverse transcriptase-PCR-based strategies
are employed; however, the diagnosis of oncogenic ALK
fusions is challenging due to the large number of
different EML4–ALK variants [28] and the possibility
of alternative partners, such as TFG and KIF5B [9,27]. The
presence of EML4–ALK is generally considered to be
mutually exclusive to EGFR or KRAS mutations (altho-
ugh one exception has been reported of a NSCLC patient
with both EML-ALK and EGFR [22]). Given this, one can
envision that future clinical investigation of NSCLC may
include a standard panel of diagnostic tests aimed at
identifying patient populations with driver mutations
such as KRAS, EGFR and ALK translocations. While treat-
ment options for patients with KRAS mutations are
limited, those falling into EGFR mutant or ALK trans-
location categories can be offered tailored molecular
therapeutic intervention.
ALK inhibitors
There are now a considerable number of interesting ALK
inhibitors(seeFigure1andTable1).Twoofthese—NVP-
TAE684 [35] and crizotinib (PF-2341066) [36]—are
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employed in a substantial number of scientific studies.
NVP-TAE684 was presented in 2007 as highly potent and
selective ALK ATP-competitive inhibitor, and was shown
to block growth in cell lines and in a mouse model of
ALCL [35]. Cells expressing oncogenic variants of ALK or
EML4–ALK fusion proteins show reduced growth when
treated with NVP-TAE684 [37,38]. Also, the ALK inhibitor
NVP-TAE684 successfully inhibited tumors in a mouse
model of EML4–ALK lung cancer [37], with mice over-
expressing EML4–ALK developing tumors with malignant
characteristics. This result confirms both the potent
oncogenic activityof the fusionkinase and the therapeutic
potential of targeted inhibitors [37]. While scientific
reports in both cell lines and mouse models have shown
NVP-TAE684tobeeffectiveagainstALKfusiononcogenes,
it is not currently in any clinical trial. Whether this is due
to pharmacologic issues with NVP-TAE684 that prevented
further clinical development by Novartis, or for other
reasons, is not clear.
Like NVP-TAE684, crizotinib (now FDA-approved as
Xalkori) is an ATP-competitive small molecule ALK
inhibitor, which also displays activity against the c-Met
receptor tyrosine kinase [36]. The rapid clinical develop-
ment of crizotinib is in part a reflection of lessons learnt
in preceding years of tyrosine kinase inhibitor develop-
ment. Crizotinib (initially known as PF-2341066) was
first described in 2007, and by 2010 the first clinical trial
results had reported promising initial results in NSCLC
patients carrying ALK translocations [39]. At the
Figure 1. Schematic overview of potential tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC)
LUNG CANCER
1.6 million diagnosed 
per year worldwide
NSCLC (80%) SCLC
EGFR ALK KRas Unknown
Gefitinib
Crizotinib LDK378
3-39 X-396
IPI-504* ASP3026
AP-26113
AF802
Other: MET, HER2, AKT, PI3CA, BRAF, MEK1 
Erlotinib
EGFR inhibitors ALK inhibitors
EML4-ALK
KIF5B-ALK
TFG-ALK
GSK1838705A
Lung cancer is divided into two clinically important groups: NSCLC, which accounts for approximately 80% of lung cancer; and small-cell lung cancer (SCLC).
Within NSCLC, a number of ALK kinase inhibitors are shown in green, with the exception of IPI-504 (marked with an asterisk), which is an Hsp90 inhibitor.
AKT; v-akt murine thymoma viral oncogene homolog 1; ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B1; EGFR,
epidermal growth factor receptor; EML, echinoderm microtubule-associated protein-like; HER2, human epidermal growth factor receptor 2; KIF5B, kinesin
family member 5B; KRas; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MEC1, mitosis entry checkpoint 1; MET, met proto-oncogene (hepatocyte
growth factor receptor); PI3CA, phosphatidylinositol-3 kinase catalytic subunit alpha; TFG, TRK-fused gene.
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2011 in Chicago, a follow-up study from this Phase I
study of crizotinib was presented, showing progression-
free survival in patients with ELM4–ALK-positive NSCLC
[40].Thistrialhasbeencarriedoutin119enrolledpatients
with advanced NSCLC, 44% of whom have received
more than three treatments before receiving oral crizotinib.
Two patients displayed a complete response (disappear-
ance of target lesions), 69 patients had a partial response,
and 31 patients were considered to have stable disease,
implying that crizotinib treatment has very real patient
benefit [39,40].
Currently, Phase III trials with crizotinib are ongoing.
Importantly, in response to ethical concerns, these Phase
III trials will allow crossover from the chemotherapy
control arm to crizotinib on failure to respond, allowing
these patients to benefit from ALK-inhibitor therapy.
Whilethe crossoveraspect ofthis trialwillmakeitdifficult
to assess the true impact on overall survival in response to
crizotinib, it will allow for patients from the chemother-
apy control arm to receive ALK-inhibitor therapy upon
failure to respond to chemotherapy. Follow up of the 82
ALK-positive patients reported by Kwak et al. [39], suggest
a significant increase in overall survival in response to
crizotinib (64% at 2 years) [41].
The results thus far suggest that while we are not yet at
the stage of ‘curing’ ALK-positive NSCLC, we may be
approaching the scenario of chronic disease management.
This brings an additional set of challenges, not least drug
toxicity. Results from ALK knockout mice, which are
viable, suggest that loss of ALK activity is not life
threatening [42]. Oral crizotinib at a therapeutic dose of
250 mg twice a day appears to be relatively well tolerated
with most complaints being Grade 1 nausea and diarrhea.
Interestingly, a significant proportion of these patients
report mild visual disturbances while taking crizotinib
[39,40]. While no function in visual development has
been described in the mouse, alterations in behavior
indicate a role for this receptor in the adult brain [42].
A potential role for ALK in the human visual system is
supported by its involvement in the maturation of the
optic lobe in the Drosophila brain [43] and the robust
expression of ALK within the lens and the neural and
pigment layer of the mouse retina [44]. The speed of
clinical application of crizotinib in NSCLC since its initial
description in 2007 is impressive, and it is now being
investigated for ALK inhibition in neuroblastoma and
ALCL (Table 1). In neuroblastoma, the ALK mutations are
activating kinase domain point mutations in the context
of the full length receptor, rather than oncogenic fusions
as in NSCLC, and they are also sensitive to ALK inhibitors
[45-49]. Furthermore, knowledge gained from the crizo-
tinib experience will hopefully pave the way for the next
wave of ALK inhibitors.
Resistance and next generation ALK inhibitors
The development of therapeutic tools for use in ALK-
driven cancers has benefited from the experience gained
Table 1. Inhibitors for anaplastic lymphoma kinase (ALK) in or expected to go to clinical trial, 2011
Company Inhibitor Clinical trial; phase G/W Aims of investigation
Pfizer Crizotinib
(Xalkori)
NCT00932893; III No Crizotinib versus standard of care in patients with advanced NSCLC
NCT01154140; III No Randomized, open-label study of the efficacy and safety of crizotinib versus
pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated
patients
NCT00939770; I/II No Young patients with relapsed or refractory solid tumors, ALCL, CNS, or NBs.
NCT01121588; I/II No Safety and efficacy in patients with tumors except NSCLC that are positive for
ALK
Novartis NVP-TAE684 N/A Not developed
LDK378 NCT01283516; I Yes Safety in ALK-positive/genetically abnormal tumors; no available data.
3-39 preclinical Yes
Chugai AF802
(CH5424802)
JapicCTI-101264; I/II Yes I. Safety, tolerability, and pharmacokinetic in NSCLC patients with ALK-fusion
gene. II. Efficacy and safety of AF802.
Infinity IPI-504* NCT01228435; II N/A Inhibitor of Hsp90, which protects other proteins from being destroyed,
possibly also EML4–ALK fusion proteins in NSCLC patients.
Astrella ASP3026 NCT01284192; I ND Safety and tolerability of ASP3026. No preclinical data available but aim for
advanced malignancies, B-cell lymphoma, solid tumors, and ALK.
Ariad AP-26113 preclinical Yes AP-26113 abrogates crizotinib-resistant mutations in EML4–ALK. Clinical
development 2011 likely.
Xcovery X-396 preclinical Yes X-396 inhibits two ALK point mutations, C1156Y and L1196M, and works in
synergy with rapamycin. May initiate clinical trials by the end of 2011.
GlaxoSmithKline GSK-1838705A preclinical Yes Abrogates ALK, and growth of ALCL, some NBs, and a subset of NSCLC.
*IPI-504 is not an ALK inhibitor, but an Hsp90 inhibitor. ALCL, anaplastic large-cell lymphoma; CNS, central nervous system; EML4, echinoderm
microtubule-associated protein-like 4; G/W, ability to inhibit gateway mutation; NB, neuroblastoma, N/A, not applicable; ND, not determined; NSCLC,
non-small cell lung cancer.
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BCL–ABL and EGFR inhibitors. However, the prolonged
survival seen with these drugs necessitates long-term
treatment, which presents a new set of problems. One
such challenge with kinase inhibitors is the development
of drug resistance, and particularly appearance of “gate-
keeper” mutations that block crizotinib binding.
Acquired inhibitor resistance is a serious complication
in cancer treatment, where the objective is a chronic
maintenance of tumor control rather than a “quick fix”.
Indeed, this has already been documented for a patient
with NSCLC who relapsed after the appearance of
C1156Y and L1196M mutations in EML4–ALK [50].
L1196M represents a mutation of the “gatekeeper”
residue, similar to the T790M gefitinib-resistance muta-
tions observed in EGFR, and T315I mutations in ABL.
Mutations in the gatekeeper site are thought to increase
theaffinityforATPsignificantly,outcompetingtheeffects
of ATP competitive inhibitors [51]. The effect of the
C1156Y mutation is unclear, although it may have an
indirect effect on crizotinib binding, and further studies
will be required to establish its mechanism.
A number of ALK inhibitors that are able to inhibit ALK
variants with “gatekeeper” mutations at L1196M have
been developed. One of these is AP26113 from Ariad,
which inhibits the growth of crizotinib-resistant H3122
cell lines and xenograft mouse models that carry the
L1196M EML4–ALK mutation [52] (Table 1). In a recent
publication, high-throughput screening and scaffold
modification resulted in CH5424802 (AF802), which
inhibits ALK activity in vitro and in mouse xenograft
models [53]. This inhibitor proved effective against both
C1156Y- and L1196M-resistant EML4–ALK mutants
[50]. The structure of the ALK kinase domain in various
forms, including several ALK-inhibitor complexes, has
recently been reported [54,55] and comparison of the
unliganded ALK catalytic domain structure with the
structure of the ALK–CH5424802 complex shows that
the inhibitor binds in the ATP pocket in DFG-in mode,
with some notable differences in comparison with
bound crizotinib [53] providing rationalization of the
ability of CH5424802 to inhibit forms of EML–ALK that
are less sensitive to crizotinib.
Two additional ALK-specific small molecule tyrosine
kinase inhibitors, X-376 and X-396, have been identified
and biologically characterized [56]. X-396 is also able to
inhibit ELM4–ALK (L1196M) and ELM4–ALK (C1156Y),
and is active in animal models of NSCLC and neuro-
blastoma. These data, in conjunction with preliminary
toxicology and pharmacokinetic data, suggest that X-396
should be an effective, well-tolerated oral treatment for
ALK-positive NSCLC, lymphoma, and neuroblastoma.
Other preclinical ALK inhibitors
A number of other promising ALK inhibitors exist.
GSK1838705A has been shown to inhibit ALK (as well
as insulin-like growth factor receptor and insulin
receptor), inhibiting the proliferation of cancer cell
lines and growth of tumor xenografts in nude mice [57]
(Table 1). A crystal structure of the ALK kinase domain in
a complex with PHA-E429 has been described [55], and
F91873 and F91874 were identified as multikinase
inhibitors with activity against ALK in a biochemical
screen in ALCL cell lines and xenograft models [58].
Cephalon have developed CEP-28122, for which little
information currently exists, and ASP3026 is an inhibitor
made by Astrella Pharma Inc. that is in Phase I clinical
trials for ALK-related malignancies (Table 1). Likewise,
few details exist concerning LDK378, an ALK inhibitor
developed by Novartis, such as its relationship to the
Novartis preclinical compound 3-39 [37,59,60]. LDK378
is currently in Phase I trials for patients with tumors
characterized by genetic abnormalities in ALK (Table 1).
In addition to the ALK inhibitors discussed above, new
molecules continue to be described, such as NMS-E628
[61], SJ-08-0025 [62], tetrahydropyridopyrazines [63],
and compounds from structural-based virtual screening
approaches [64]. Other compounds, such as the Hsp90-
inhibitor geldenamycin derivatives IPI-504 and 17-AAG,
appear to have effects in NSCLC patients with ALK
translocations,andthiseffectappearstoextendtoELM4–
ALK (L1196M) suggesting they may be useful in over-
coming crizotinib-resistant tumors [52,65,66]. A number
ofclinicaltrialsareinprogress(Table1)andtheresultsof
these eagerly awaited.
ALK inhibitors and NSCLC: future and reflection
A great deal of progress has been made since the early
days of ALK inhibitors [67], and a substantial number of
patent applications for ALK inhibitors have been filed
[68], some of which have now been translated into
realistic options for clinical use. The rapid pace of ALK
drug development is being accompanied by similar
progress in robust diagnostics and coordinated
approaches to NSCLC treatments. Many questions and
challenges remain for the future, especially in terms of
use of ALK inhibitors in combination with other
signaling inhibitors and the rational design of trials to
test these. In spite of the increasing body of impressive
data and elegant studies published, we should remember
that the response of patients to ALK inhibitors will
probably throw up a multitude of unexpected questions
and challenges. The human body and the complex
interplay with the evolving and adapting tumors never
cease to confound scientists and clinicians alike and the
unpredictable can be expected. Finally, it is important
Page 5 of 9
(page number not for citation purposes)
F1000 Medicine Reports 2011, 3:21 http://f1000.com/reports/m/3/21to bear in mind that if ALK inhibitors work in patients,
we should heartily thank all those who have tirelessly
worked over the years to bring them to therapeutic
realization. Such efforts allow us to look forward to a
more optimistic era of treatment for NSCLC patients
based on molecular treatments tailored to their tumor
type.
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